Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control
Withdrawn before enrolling · Phase 2 · Has a placebo group
Conditions studied: COPD
In brief
The purpose of this study is to evaluate the safety and efficacy of inhaled formoterol fumarate (7.2 and 9.6 µg ex-actuator) compared to placebo and Foradil Aerolizer in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
Key facts
- Study ID
- NCT01043601
- Run by
- Pearl Therapeutics, Inc.
- People needed
- 0
- Starts
- 2010-07-01
- Expected to finish
- 2011-04-01
- Last updated by the study team
- 2014-07-11
Who can join
Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Spartanburg Medical Research — Spartanburg, South Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.